A Novel Bispecific T Cell Engager (UMG2BTCE) Targeting CD1a-CD3e Is Effective Against Cortical-Derived Acute Lymphoblastic Leukemia

被引：0
|
作者：
Riillo, Caterina [1 ]
Caracciolo, Daniele [1 ]
Grillone, Katia [1 ]
Polera, Nicoletta [1 ]
Juli, Giada [1 ]
Scionti, Francesca [2 ]
Ascrizzi, Serena [1 ]
Tuccillo, Franca Maria [3 ]
Bonelli, Patrizia [3 ]
Arbitrio, Mariamena [4 ]
Di Martino, Maria Teresa [1 ]
Tagliaferri, Pierosandro [1 ]
Tassone, Pierfrancesco [1 ,5 ]
机构：
[1] Magna Graecia Univ Catanzaro, Catanzaro, Italy
[2] Italian Natl Council CNR, IRIB, Messina, Italy
[3] Ist Nazl Tumori Fdn G Pascale, Naples, Italy
[4] IRIB CNR, Catanzaro, Italy
[5] Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Philadelphia, PA USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-153043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2259
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Evaluating the cytotoxic effectiveness of a novel TCR-like bispecific T cell engager targeting the PR1/HLA-A2 leukemia antigen
    Herrmann, Amanda Cernosek
    Im, Jin Seon
    He, Hong
    Anna, Sergueeva
    Lu, Sijie
    Molldrem, Jeffrey
    CANCER RESEARCH, 2018, 78 (13)
  • [32] A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia
    Nair-Gupta, Priyanka
    Diem, Michael
    Reeves, Dara
    Wang, Weirong
    Schulingkamp, Robert
    Sproesser, Katrin
    Mattson, Bethany
    Heidrich, Bradley
    Mendonca, Mark
    Joseph, Jocelin
    Sendecki, Jocelyn
    Foulk, Brad
    Chu, Gerald
    Fink, Damien
    Jiao, Qun
    Wu, Sheng-Jiun
    Packman, Kathryn
    Elsayed, Yusri
    Attar, Ricardo
    Gaudet, Francois
    BLOOD ADVANCES, 2020, 4 (05) : 906 - 919
  • [33] Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Westervelt, Peter
    Roboz, Gail J.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Lee, Sangmin
    Rettig, Michael P.
    Han, Tae H.
    Guenot, Jeanmarie
    Feldman, Eric J.
    DiPersio, John F.
    BLOOD, 2018, 132
  • [34] A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
    Murthy, Guru Subramanian Guru
    Kearl, Tyce
    Cui, Weigo
    Johnson, Bryon
    Hoffmeister, Karin
    Harrington, Alexandra
    Szabo, Aniko
    Badar, Talha
    Duvall, Adam
    Leonard, Jessica Taft
    Yi, Cecilia Ysabel Arana
    Baim, Arielle
    Yaghoubi, Shahriar
    Shah, Bijal D.
    Stock, Wendy
    Atallah, Ehab L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome.
    Boissel, Nicolas
    de Botton, Stephane
    Thomas, Xavier G.
    Rao, Ercole
    Bonnevaux, Helene
    Rubin-Carrez, Chantal
    Guerif, Stephane
    Beys, Eric
    Gosselin, Alice
    Bauchet, Anne-Laure
    Novikov, Valery
    Fernandes, Elma
    Wiederschain, Dmitri
    Palatinsky, Emanuel A.
    Hsu, Karl
    Fraenkel, Paula Goodman
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Generation of a novel ROR1 x CD3 bispecific T-cell engager for better tumor killing and minimal cytokine release
    Wu, Danqing
    Gong, Shiyong
    Wu, Xuan
    Naren, Gaowa
    Dong, Liqin
    Lensky, Stephan
    Wu, Chengbin
    CANCER RESEARCH, 2024, 84 (07)
  • [37] UMG1, a novel humanized monoclonal antibody against a glysosylated-CD43-related epitope, induces antibody-dependent cellular cytotoxicity (ADCC) on human T-cell acute lymphoblastic leukemia cells
    Botta, Cirino
    Cantafio, Maria E. Gallo
    Buracchi, Chiara
    Siciliano, Maria A.
    Cuce, Maria
    Riillo, Caterina
    Tuccillo, Franca M.
    Caracciolo, Daniele
    Altomare, Emanuela
    Arbitrio, Mariamena
    Di Martino, Maria T.
    Rossi, Marco
    Biondi, Andrea
    Gaipa, Giuseppe
    Tagliaferri, Pierosandro
    Tassone, Pierfrancesco
    CANCER RESEARCH, 2018, 78 (13)
  • [38] Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia (vol 13, 30, 2020)
    Dai, Hanren
    Wu, Zhiqiang
    Jia, Hejin
    Tong, Chuan
    Guo, Yelei
    Ti, Dongdong
    Han, Xiao
    Liu, Yang
    Zhang, Wenying
    Wang, Chunmeng
    Zhang, Yajing
    Chen, Meixia
    Yang, Qingming
    Wang, Yao
    Han, Weidong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [39] Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment
    Bonnevaux, Helene
    Guerif, Stephane
    Albrecht, Jana
    Jouannot, Erwan
    De Gallier, Thibaud
    Beil, Christian
    Lange, Christian
    Leuschner, Wulf Dirk
    Schneider, Marion
    Lemoine, Cendrine
    Caron, Anne
    Amara, Celine
    Barriere, Cedric
    Siavellis, Justine
    Bardet, Valerie
    Luna, Ernesto
    Agrawal, Pankaj
    Drake, Donald R.
    Rao, Ercole
    Wonerow, Peter
    Carrez, Chantal
    Blanc, Veronique
    Hsu, Karl
    Wiederschain, Dmitri
    Fraenkel, Paula G.
    Virone-Oddos, Angela
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [40] Induction of NK and T Cell Immune Responses Against Leukemia Cells By Bispecific NKG2D-CD16 and-CD3 Fusion Proteins
    Koerner, Samuel
    Kanz, Lothar
    Grosse-Hovest, Ludger
    Jung, Gundram
    Salih, Helmut R.
    BLOOD, 2015, 126 (23)
12345